Company Profile
Olema Pharmaceuticals, Inc. Stock Price, News & Analysis
- Ticker:
- OLMA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.80 USD (+1.90%)
Close
Last updated: August 6, 2026
934M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, OLMA closed up 1.90% at $11.80. No new same-company headline was identified in the current news window.
Company overview
Endocrine-Driven Cancer Company
Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer.
Palazestrant
Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast cancer.
OP-3136
OP-3136 is an oral KAT6 inhibitor intended to complement endocrine therapy and address transcriptional drivers of resistance.
Future catalysts
Topline results from the Phase 3 OPERA-01 palazestrant study are expected in fall 2026.
Initial Phase 1 clinical data for OP-3136 are scheduled for presentation at ASCO 2026.
Recent news
- 01
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Olema Pharmaceuticals, Inc.
- 02
- 03
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Source: Olema Pharmaceuticals, Inc.
- 04
Olema Oncology to Participate in Upcoming Investor Conferences
Source: Olema Pharmaceuticals, Inc.
- 05
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Source: Olema Pharmaceuticals, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Olema Pharmaceuticals, Inc. (OLMA)?
Olema Pharmaceuticals, Inc. (OLMA) most recently closed at 11.80 USD, a +1.90% move versus the previous session.
What is the market cap of Olema Pharmaceuticals, Inc. (OLMA)?
Olema Pharmaceuticals, Inc. currently has a market capitalization of 934M USD on BioPharmSignal.
What does Olema Pharmaceuticals, Inc. do?
Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast cancer. OP-3136 OP-3136...
On which exchange is OLMA stock listed?
Olema Pharmaceuticals, Inc. (OLMA) is associated with NASDAQ, United States, Biopharma.
What is OP-3136?
Initial Phase 1 clinical data for OP-3136 are scheduled for presentation at ASCO 2026.
Which conditions is Olema Pharmaceuticals, Inc. targeting with OP-3136?
Olema Pharmaceuticals, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Olema Pharmaceuticals, Inc. describe recent progress with OP-3136?
Initial Phase 1 clinical data for OP-3136 are scheduled for presentation at ASCO 2026.
What is OPERA-01?
Topline results from the Phase 3 OPERA-01 palazestrant study are expected in fall 2026.